Urology Practice Management - December 2020, Vol 6, No 4

The combination of cabozantinib (Cabometyx), a second-generation tyrosine kinase inhibitor (TKI), plus nivolumab (Opdivo), an immune checkpoint inhibitor, significantly improved overall survival (OS) and doubled the objective response rates (ORR) compared with the current standard, sunitinib (Sutent), in treatment-naïve patients with advanced renal-cell carcinoma (RCC), according to the results of the phase 3 CheckMate-9ER clinical trial. Read More ›

The COVID-19 pandemic has had a profound impact on cancer care delivery in the United States—for the worse, but also for the better. Read More ›

Cancer health disparities remain a challenge in the United States, despite some strides being made to reduce these disparities, according to a new report from the American Association for Cancer Research (AACR) that was released in a virtual presentation on September 16, 2020. Read More ›

On December 1, 2020, the FDA approved Gallium 68 PSMA-11 (Ga 68 PSMA-11; University of California), the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)- positive lesions in men with prostate cancer. Read More ›

PARP inhibition is moving on from breast and ovarian cancer to the treatment of patients with prostate cancer and BRCA1/2 mutation. Read More ›

The COVID-19 pandemic has led to a massive boom in telehealth, according to Heidi Kocher, Esq, Partner, Liles Parker, PLLC, Plano, TX. Read More ›

The American College of Rheumatology has issued a position statement on pharmacovigilance, underlining its support for continued monitoring of new drugs and their side effects after they have been approved by the US Food and Drug Administration, which is important in biosimilar development. Read More ›

San Diego, CA—At the 2017 American College of Rheumatology (ACR) Annual Meeting, Angus Worthing, MD, Arthritis and Rheumatism Associates, Washington, DC, and Chair, ACR Government Affairs Committee, provided a legislative and regulatory update. Discussion topics included ACR contributions on policy development and change, as well as regulatory initiatives currently before Congress and how they may impact rheumatology practices in the future.

Read More ›

Urology Practice Management logo
Subscribe to Urology Practice Management

Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or e‑Newsletters.

UPM e-Newsletter
UPM print publication